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Torulopsis glabrata, an opportunist pathogen in immunosuppressed patients, is resistant to many antifungal
agents, and there are no established treatment regimens for this organism. The mouse model was used to
evaluate treatment with D0870, amphotericin B, fluconazole, and their combination. Mice were immunosup-
pressed with 5 mg of gold sodium thiomalate given intraperitoneally 1 day prior to intravenous infection with
108 T. glabrata cells. Treatment with a new antifungal triazole, D0870, at doses ranging from 1 to 50 mglkg of
body weight administered per os either daily or on alternate days; fluconazole at 100 mg/kg twice a day per os;
or amphotericin B at 3 mg/kg/day intraperitoneally was begun 1 day after infection. Treatment for 5 days was
followed by sacrifice 2 days later for determining CFU counts in spleen and kidney tissue. For a
fluconazole-sensitive isolate (MIC of D0870, < 1.25 ,ug/ml), D0870 at 5 mg/kg/day significantly reduced
counts in kidney and spleen tissue (P < 0.05), amphotericin B was modestly effective, and the combination of
D0870 (25 mg/kg) and amphotericin B (3 mg/kg) was markedly more effective than either drug alone (P <
0.01). Three additional isolates were resistant in vitro to D0870 (MIC, 4 p,g/ml). No reduction in CFU in
kidney or spleen tissue was observed with D0870 when compared with counts in control tissue. D0870 is
eflective in vivo against at least some isolates of T. glabrata and when combined with amphotericin B can exert
additive eflects.
Torulopsis glabrata (Candida glabrata), an opportunistic
pathogen, has been seen increasingly in immunosuppressed
AIDS and transplant patients, where it has been reported in up
to 25% of patients with fungemia (1, 6, 11). To date, there is no
standard therapy for infection with this organism, which has
shown variable in vitro susceptibility to present antifungal
agents including amphotericin B, fluconazole, and flucytosine
(7). DO870, a new triazole antifungal agent, has been shown to
have excellent activity in vivo and in vitro against Candida
albicans and Cryptococcus neoformans, including fluconazole-
resistant isolates in normal and immunocompromised mice (2,
3, 5, 13). Using an immunosuppressed mouse model of T.
glabrata infection, we evaluated the effect of amphotericin B,
fluconazole, and DO870 against disseminated T. glabrata in-
fection.
MATERIALS AND METHODS
Animals. Outbred ICR Harlan Sprague-Dawley male mice,
20 to 25 g, were housed five per cage with free access to water
and food.
Immunosuppression. Mice were immunosuppressed with
either 5 mg of gold sodium thiomalate (Myochrysine; Merck
Sharp & Dohme, West Point, Pa.) given intraperitoneally 1 day
prior to infection (8, 17) or 5-fluorouracil (5FU; Hoffman-
LaRoche, Nutley, N.J.) administered intravenously at 150
mg/kg of body weight. Immunosuppression was verified by
leukocyte counts performed the day after administration of the
gold sodium thiomalate or 5FU as well as at 5, 10, and 15 days
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posttreatment. With both agents, the peripheral blood leuko-
cyte counts were reduced to less than 100/mm3 for 15 days.
Organisms. Four clinical isolates of T glabrata were ob-
tained from the Fungal Research Laboratory of M. G. Rinaldi,
University of Texas Health Science Center at San Antonio.
One day prior to challenge, the organisms were subcultured to
50 ml of brain heart infusion (BHI) broth (BBL, Cockeysville,
Md.). The fungi were incubated on a shaker at 37°C overnight,
washed twice with 0.9% NaCl, quantified with a hemacytom-
eter, and adjusted to the desired concentration in normal
saline. The counts were verified by determining CFU counts
with 10-fold serial dilutions in 0.9% NaCl. Each mouse was
infected with 1.1 x 108 to 7 x 108 CFU/ml in the lateral tail
vein given in a 0.2-ml volume. The T. glabrata cells were
agitated between each injection to achieve a uniform suspen-
sion.
Activity in vitro. The in vitro susceptibility studies were
performed by the broth macrodilution technique proposed by
the National Committee for Clinical Laboratory Standards (7).
The medium was RPMI 1640 with glutamine, buffered by
MOPS (morpholinepropanesulfonic acid) at pH 7.0 (American
Bioganics, Niagara Falls, N.Y.). The inoculum was prepared
from 24-h Sabouraud dextrose agar (Difco Laboratories, De-
troit, Mich.) subcultures of T. glabrata incubated at 35°C.
Colonies of T. glabrata were suspended in 5 ml of sterile
distilled water, and the cell density was adjusted with a
spectrophotometer to a 0.5 McFarland standard at a 530-nm
wavelength. The working suspension was a 1:100 dilution of
the organisms followed by a 1:20 dilution of the suspension
with RPMI broth medium. A volume of 0.9 ml of the adjusted
solution was dispensed into tubes containing 0.1 ml of 10 times
the concentrations of the drugs to be tested. The test tubes
were incubated at 35°C for 48 h. The MIC of amphotericin B
was the lowest concentration that permitted no visible growth.
For the azoles, the MIC was the lowest concentration that
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TABLE 1. MICs for four isolates of T. glabrataa
MIC (,ug/ml) of:
Isolate no.
D08790 AmB FLU
1 <0.125 0.5 2
2 4 0.5 16
3 4 0.5 64
4 4 1.0 >64
a Abbreviations: AmB, amphotericin B; FLU, fluconazole.
produced at least 80% inhibition of growth in comparison with
that of the control. Inconsistent results were rechecked by
duplicate testing of the isolates. Quality control strains of T.
glabrata (ATCC 90029 and ATCC 90030) were included on
each day of repeated testing. As shown in Table 1, the MIC of
D0870 for isolate 1 was <0.125 jig/ml and that for isolates 2,
3, and 4 was 4 ,ug/ml. The latter isolates were considered
resistant, since the MIC was the highest observed in our study
and agreed with the data of Peng and Galgiani (16), who
reported a MIC range of 0.125 to 4.0 jig/ml for T. glabrata.
Antifungal agents. DO870 was obtained from Zeneca Phar-
maceuticals (Macclesfield, Cheshire, England). Fluconazole
was provided by Pfizer-Roerig Pharmaceuticals (New York,
N.Y.), and amphotericin B was obtained from Lyphomed
(Deerfield, Ill.). The D0870 was prepared daily in 0.5%
polysorbate (Tween 80), sonicated, and administered per os by
an esophageal cannula (gavage) (p.o.) in a volume of 0.2 ml per
dose. Amphotericin B was diluted to the desired concentration
in 5% dextrose in water and administered at a volume of 0.2 ml
intraperitoneally. Fluconazole was suspended in 0.3% Noble
agar (Difco Laboratories) and administered at 0.2 ml p.o. via
gavage.
Treatment regimens. After infection, the mice were ran-
domized into treatment groups of 10 mice each. Drug therapy
was begun the day following the infecting challenge. The mice
were treated for 5 days with either amphotericin B (3 mg/kg/
day) intraperitoneally, fluconazole (100 mg/kg twice a day
[BID]) p.o., or D0870 (25, 10, 5, or 1 mg/kg/day or 10 or 5
mg/kg on alternate days [q.o.d.]) p.o. Other groups of mice
were treated with a high-dose combination of amphotericin B
(3 mg/kg/day) plus D0870 (25 mg/kg/day) or a low-dose
combination of amphotericin B (2 mg/kg/day) plus D0870 (1
mg/kg/day). Control mice received 0.2 ml of 0.3% Noble agar
p.o. Forty-eight hours after the last dose of antifungal agent,
the mice were anesthetized with methoxyflurane (Metophane;
Pitman-Moore, Washington Crossing, N.J.) and sacrificed by
cervical dislocation. Both kidneys and the spleen were excised
by a sterile technique, weighed, and homogenized in 2 ml of
sterile 0.9% saline with 60 jig of amikacin per ml and 60 jig of
piperacillin per ml. The homogenates were diluted by serial
10-fold dilution in saline, and 0.1 ml of each dilution and the
undiluted homogenate were cultured in duplicate on Sab-
ouraud dextrose agar for 48 h. CFU per gram of tissue was
calculated. The minimal count was 18 CFU/g of tissue.
Statistical analysis. One-way analysis of variance was used.
Multiple comparisons were made by Tukey's Studentized
Range test using the logs of the CFU counts and were
analyzed. A P value of <0.05 was considered statistically
significant.
RESULTS
Table 1 presents in vitro susceptibilities. Isolate 1 was
susceptible to both D0870 and fluconazole. Isolates 2 to 4
were resistant to D0870 and fluconazole.
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FIG. 1. Comparison of CFU per gram of tissue in control (Con)
mice and mice treated with fluconazole (FLU) (100 mg/kg BID) or
D0870 (50 mg/kg/day) after immunosuppression with 5FU (A and B)
or gold sodium thiomalate (C and D). Panels A and C show results for
kidney tissue, and panels B and D show results for spleen tissue (n =
10).
Immunosuppression. 5-FU or gold sodium thiomalate re-
duced the peripheral leukocyte counts to <100/mm3 in the
mice 1 day following treatment. Previous experiments with
5FU showed that 150 mg/kg similarly reduced the leukocyte
counts with the least toxicity for the period of treatment
(unpublished data). Because we wished to evaluate T glabrata
in mice with impaired macrophage and neutrophil function, we
used gold sodium thiomalate for immunosuppression (13) in
the subsequent studies. A comparison of mice immunosup-
pressed with gold sodium thiomalate versus 5FU and treated
with fluconazole or D0870 is shown in Fig. 1. Overall, D0870
(50 mg/kg/day) was more active than fluconazole (100 mg/kg/
day) in reducing the CFU burden in both kidney and spleen
tissue, regardless of the method used for immunosuppression
(P < 0.05). There was a modest but significant reduction in the
CFU per gram of kidney tissue when the mice immunosup-
pressed with gold sodium thiomalate were treated with flucon-
azole (P < 0.05), but there was not a significant reduction in
the CFU counts in kidneys of mice immunosuppressed with
5FU. In both groups, there was a significant reduction in the
CFU burden in the spleen when mice were treated with D0870
instead of fluconazole. In all of the subsequent studies, the
mice were immunosuppressed with gold sodium thiomalate.
Dose range studies. Results for infections with isolate 1
treated with D0870 at various concentrations ranging from 1
to 25 mg/kg/day are shown in Fig. 2. Daily dosing at 25
mg/kg/day suppressed the spleen tissue CFU burden the most.
At 5 mg/kg/day (kidney) and 1 mg/kg/day (spleen), the tissue
CFU burden was also reduced. However, q.o.d. dosing with
D0870 at 10 mg/kg (a dose equivalent to 5 mg/kg/day for 2
days) did not significantly reduce CFU in either the kidneys or
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FIG. 2. Dose range study comparing effects of daily dosing with
DO870 at 25, 10, 5, and 1 mg/kg/day with D0870 administered q.o.d.
at 10 and 5 mg/kg. Panels: A, kidney; B, spleen. Con, control; n = 10.
FIG. 4. Dose range study comparing efficacies of D0870 at 25, 10,
and 5 mg/kg/day for treatment of infection with isolate 2. Panels: A,
kidney; B, spleen. Con, control; n = 10.
the spleen. Therefore, despite a slow clearance, a D0870
elimination half-life of 30 h (2a), daily dosing is required.
Combination therapy. The high-dose combination of
D0870 (25 mg/kg/day) and amphotericin B (3 mg/kg/day)
decreased the CFU per gram of kidney tissue (P < 0.05) more
than either antifungal agent alone for isolate 1, the flucon-
azole-susceptible isolate (Fig. 3A). An additive effect was
undetectable for the spleen CFU counts at these antibiotic
concentrations (Fig. 3B). Low-dose combination treatment
with amphotericin B (2 mg/kg/day) and D0870 (1 mg/kg/day)
showed no additive effect (Fig. 3C and D).
Resistant strains. When mice infected with T. glabrata
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FIG. 3. Comparison of treatment with D0870 at 25 mg/kg/day,
amphotericin B (AMB) at 3 mg/kg/day, and the combination (Both)
(panels A [kidney] B [spleen]) and D0870 at 1 mg/kg/day, amphoter-
icin B at 2 mg/kg/day, and the combination (panels C [kidney] and D
[spleen]). Con, control; n = 10.
isolates 2, 3, and 4 (DO870 MIC, 4 ,ug/ml) were treated with 5,
10, or 25 mg of D0870 per kg per day, no reduction in CFU
per gram of kidney or spleen tissue was detected (Fig. 4, isolate
2). At 100 mg/kg/day, D0870 had no effect on either the kidney
or the spleen tissue CFU burden (result not shown).
DISCUSSION
Disseminated T glabrata infection was achieved in mice
immunosuppressed with either gold sodium thiomalate or 5FU
with an inoculum of 108 CFU/ml. Organs infected in prelimi-
nary studies included the spleen, kidneys, liver, and lungs.
Cell-mediated immunity is believed to play an important role
in immunity to fungal infections, and macrophages may con-
tribute to the release of polypeptide cytokines which may alter
the antimicrobial activity of effector cells such as neutrophils.
Kowanko et al. (10) showed that granulocyte macrophage
colony-stimulating factor enhanced the in vitro killing of T
glabrata. We therefore examined models with suppression of
neutrophils (5FU) as well as inhibition of macrophage function
(gold sodium thiomalate). Since the target organ for T. glabrata
is the kidney and since D0870 concentrates in the reticuloen-
dothelial system, the kidneys and spleen were chosen for these
studies.
D0870 was more effective than fluconazole for treatment of
infection with a fluconazole- and D0870-susceptible isolate of
T glabrata, regardless of the method of immunosuppression. It
was not, however, active against isolates of T glabrata which
are resistant in vitro to fluconazole and D0879. Ross et al. (18)
suggested the in vitro breakpoint for D0870 to be a MIC of
c2.5 ,ug/ml. Peng and Galgiani (16) showed similar MICs for
T. glabrata ranging from 0.125 to 4.0 ,ug/ml, which were 32 to
16 times higher than those typical for C. albicans (median,
0.0037 ,g/ml) or C. neoformans (median, 0.0075 ,ug/ml). No
standards for susceptibility or resistance have been established
for T. glabrata. Although more isolates will need to be exam-
ined, it appears from our in vivo studies that a D0870 MIC of
4 ,ug/ml may correspond to resistance of T. glabrata.
Our results showed that although D0870 has a long half-life
of 30 h, q.o.d. dosing was not effective in vivo with D0870
administered at 5 or 10 mg/kg q.o.d. compared with 5 or 10
mg/kg/day. This is in contrast to reports by Edwards et al. (4,
5), which showed that five oral doses of D0870 at 5 mg/kg at
48-h intervals were protective for treatment of C. albicans
infection. For treatment of murine cryptococcal meningitis,
D0870 at 10 mg/kg q.o.d. was superior to fluconazole (2). Our
results are in agreement with the latter study, which also
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showed D0870 at 50 mg/kg to be superior to fluconazole.
Combination therapy with amphotericin B (3 mg/kg/day) and
D0870 (25 mg/kg/day) was significantly better than either
antifungal agent alone in reducing the isolate 1 CFU burden in
kidney tissue.
D0870, a new triazole, has exhibited excellent antifungal
activity against systemic murine infections with C. neoformans
and C. albicans in both kidney and brain tissue of normal and
immunocompromised mice (4). D0870 is also active in vitro
against fluconazole-resistant C. albicans (4). In vivo, D0870 is
reported to be 5- to 25-fold more potent than fluconazole for
treatment of murine vaginal and systemic infections (3) and 2-
to 7-fold superior to fluconazole in normal mice versus 3- to
90-fold superior in mice immunosuppressed with either corti-
sone or cyclophosphamide (14).
The kidney is the target organ of systemic Candida infection
in mice. The treatment of systemic Candida infection in
immunocompromised patients continues to be a major prob-
lem. Infections respond poorly to treatment with antifungal
drugs, and cure is dependent on reestablishment of host
resistance (11). T. glabrata is often found as a urinary tract
pathogen causing cystitis and pyelonephritis and is reported to
account for 25 to 33% of positive urine cultures for immuno-
compromised hosts (15). T. glabrata is often more resistant
than C. albicans and is therefore more difficult to treat.
Experimental data indicate that neither amphotericin B nor
the triazoles (fluconazole and itraconazole) are able to de-
crease the number of CFU in the kidneys of persistently
neutropenic mice with systemic C. albicans infection (19).
D0870 showed no in vivo effect with D0870-resistant isolates
which had variable in vitro susceptibility to fluconazole. In
contrast, D0870 gave protection with a fluconazole-DO870-
susceptible isolate for which the D0870 MIC was <0.125
,ug/ml, and D0870 was superior to fluconazole for this strain.
This is in contrast to results reported with Candida krusei,
another more resistant yeast species, with which survival was
increased but D0870 failed to reduce the yeast burden in the
kidneys of immunosuppressed mice (9).
D0870 was effective in vivo against at least some strains of
T. glabrata and combined with amphotericin B exerted some
additive effects. The maximal dose of D0870 has not been
determined for humans, and it is uncertain whether the higher
doses which may be required for effective treatment of T.
glabrata infection will be clinically effective or tolerated. Fur-
ther studies with neutropenic models, both humans and ani-
mals, are needed, not only to test this agent against more
isolates of T glabrata but also to evaluate the use of prolonged
therapy and to determine the optimal dosages.
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